Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard A. Heyman sold 1,270 shares of the firm's stock in a transaction on Monday, April 15th. The stock was sold at an average price of $19.99, for a total value of $25,387.30. Following the completion of the transaction, the director now owns 137,155 shares of the company's stock, valued at approximately $2,741,728.45. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Enliven Therapeutics Stock Down 5.4 %
NASDAQ:ELVN opened at $19.94 on Tuesday. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $26.00. The stock has a market capitalization of $821.53 million, a PE ratio of -9.10 and a beta of 1.06. The stock's 50-day moving average price is $16.88 and its 200-day moving average price is $14.25.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. Sell-side analysts expect that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Enliven Therapeutics
The biggest energy story ever?
From Porter & Company | Ad
Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…
For the full story, click here.
Several institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company's stock worth $170,000 after buying an additional 1,029 shares during the last quarter. Deutsche Bank AG boosted its holdings in Enliven Therapeutics by 16.7% in the 3rd quarter. Deutsche Bank AG now owns 10,890 shares of the company's stock worth $149,000 after buying an additional 1,559 shares during the last quarter. Legal & General Group Plc boosted its holdings in Enliven Therapeutics by 8.9% in the 3rd quarter. Legal & General Group Plc now owns 19,665 shares of the company's stock worth $269,000 after buying an additional 1,610 shares during the last quarter. Tower Research Capital LLC TRC acquired a new stake in Enliven Therapeutics in the 1st quarter worth about $36,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Enliven Therapeutics by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 158,440 shares of the company's stock worth $2,193,000 after buying an additional 1,809 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, Mizuho started coverage on Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a "buy" rating and a $34.00 target price for the company.
View Our Latest Stock Report on ELVN
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
